Back to top
more

Nkarta (NKTX)

(Delayed Data from NSDQ)

$6.87 USD

6.87
978,270

+0.05 (0.73%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $6.87 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for NKTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Nkarta, Inc. [NKTX]

Reports for Purchase

Showing records 1 - 19 ( 19 total )

Company: Nkarta, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/25/2024

Company Report

Pages: 6

New Translational Data Validate That CAR-NK Therapy Could be Ideally Suited For Autoimmune Diseases

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 25.00

Research Provided by a Third Party

Company: Nkarta, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

03/22/2024

Company Report

Pages: 6

Prioritizing Autoimmune Diseases For Development Moving Forward; 4Q23 Financials Reported

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 25.00

Research Provided by a Third Party

Company: Nkarta, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

01/16/2024

Company Report

Pages: 7

NKX019 Demonstrates Deep B Cell Aplasia in NHL Patients; Increasing PT to $22

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 25.00

Research Provided by a Third Party

Company: Nkarta, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

12/11/2023

Company Report

Pages: 4

Durability for NKX101 Flu/Ara-C Cohort Presented at ASH Looks Positive

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Nkarta, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

11/10/2023

Company Report

Pages: 5

3Q23 Recap: AML Flu/Ara-C Update to Be Presented at ASH; Updates Across the Pipeline Expected in 2024

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Nkarta, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

10/18/2023

Company Report

Pages: 8

Nkarta Joins the Race for Cell Therapies in Autoimmune Diseases; Setback in NHL Leads Us to Lower Our PT to $10

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 12.50

Research Provided by a Third Party

Company: Nkarta, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

08/11/2023

Company Report

Pages: 5

2Q23 Recap: NKX019 Data Update Expected in 2H23 and NKX101 Update Expected in 1H24

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Nkarta, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

06/27/2023

Company Report

Pages: 7

NKX101 Flu/Cy Data Disappoint Though Initial Flu/ Ara-C Cohort Data Look Positive; Lowering PT to $16

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 12.50

Research Provided by a Third Party

Company: Nkarta, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

05/12/2023

Company Report

Pages: 5

1Q23 Recap: NKX101 AML Data in 2Q23 Could be a Significant Catalyst

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Nkarta, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

03/17/2023

Company Report

Pages: 6

4Q22 Take: We Believe Expectations For AML Data in 1H23 are Low, Creating an Attractive Buying Opportunity

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 12.50

Research Provided by a Third Party

Company: Nkarta, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

01/17/2023

Industry Report

Pages: 7

Noteworthy Discussion Points From Our Meetings at

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 12.50

Research Provided by a Third Party

Company: Nkarta, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

12/05/2022

Company Report

Pages: 4

Winning Data Streak Continues With Positive NKX019 Phase 1 Update

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Nkarta, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

11/10/2022

Company Report

Pages: 6

3Q22 Take: Additional NKX019 Data Expected in 4Q22 and NKX101 Data Expected 1H23

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 12.50

Research Provided by a Third Party

Company: Nkarta, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

08/12/2022

Company Report

Pages: 5

2Q22 Take: Additional Data From NKX101 and NKX019 Expected 2H22

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Nkarta, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

05/13/2022

Company Report

Pages: 5

1Q22 Take: Additional NKX101 and NKX019 Data Expected in 2H22

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Nkarta, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

04/25/2022

Company Report

Pages: 4

Two Solid Data Sets Are Better Than One, Increasing PT to $36

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Nkarta, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

03/18/2022

Company Report

Pages: 5

4Q21 Take: NKX101 Data in 1H22 Could Be a Major De-Risking Event for the Platform

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Nkarta, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

03/08/2022

Company Report

Pages: 81

CAR-NK Therapy Could Potentially Take CART Therapy Off-the-Shelf; Initiate at Buy and $25 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party

Company: Nkarta, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for NKTX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party